Worth reading
32Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
-127
¥ millionWording
Conditional
How definitive the wording is.Items stated in the management plan
ProgressWhat happened to the previous plan31 December 2025: ¥3,718 million (non-compliance) → Not disclosed
Statements about the use of capital
Self-assessment of PBR and share priceThe company states that it will clarify the assumptions used to calculate market capitalization and its approach to enhancing corporate value, but the current assessment and figures for PBR are Not disclosedPBR is a measure of how many times the share price is the book value per share.
Key initiatives
01Selectivity and Concentration in Business
02Clarification of medium-term targets and milestones
03More comprehensive explanations regarding market capitalization and PBR
04Enhancement of IR activities (more continuous and constructive dialogue with investors)
Plan assumptionsMarket capitalization is calculated by multiplying the number of listed shares and other securities at the end of the fiscal year by the average of the daily closing prices in trading sessions on the Tokyo Stock Exchange during the 3-month period preceding the end of the fiscal year.
Risks identified by the company
If the company fails to meet the market capitalization criterion during the improvement period ending 31 December 2026, the Tokyo Stock Exchange will designate it as a security under supervision.
If compliance with the market capitalization criterion is not confirmed in the subsequent review, the company will be designated as a security subject to delisting and will be delisted on 1 July 2027.
| Item | Details |
|---|---|
| Plan name | Plan for Compliance with the Listing Maintenance Criteria (Including the Improvement Period) |
| Plan period | Through 31 December 2026 |
| Progress against the plan | Progress |
| Self-assessment of PBR and share price | The company states that it will clarify the assumptions used to calculate market capitalization and its approach to enhancing corporate value, but the current assessment and figures for PBR are Not disclosed |
| Plan assumptions | Market capitalization is calculated by multiplying the number of listed shares and other securities at the end of the fiscal year by the average of the daily closing prices in trading sessions on the Tokyo Stock Exchange during the 3-month period preceding the end of the fiscal year. |
| Key initiatives | Selectivity and Concentration in Business, Clarification of medium-term targets and milestones, More comprehensive explanations regarding market capitalization and PBR, Enhancement of IR activities (more continuous and constructive dialogue with investors) |
| Results under the previous plan | 31 December 2025: ¥3,718 million (non-compliance) → Not disclosed |
| Risks identified | If the company fails to meet the market capitalization criterion during the improvement period ending 31 December 2026, the Tokyo Stock Exchange will designate it as a security under supervision., If compliance with the market capitalization criterion is not confirmed in the subsequent review, the company will be designated as a security subject to delisting and will be delisted on 1 July 2027. |
| Publication date | 14 August 2026 |
Items this document does not state (16)
Sales TargetOperating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalTotal investment planInvestment amount by sectorSegment targetNon-financial targetsReason for revision or withdrawalSize of the Target MarketDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company proceeded with the concentration of management resources on core businesses centered on its physician value-creation business, the restructuring of non-core businesses, the strengthening of its earnings base through business structural reforms, the clarification of its growth strategy and capital policies, and the enhancement of its IR activities.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.